Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an announcement.
ASKA Pharmaceutical Holdings reported consolidated net sales of 54.4 billion yen for the third quarter of FY2025, a 9.1% year-on-year increase and a record-high level, driven by steady domestic performance and growing contributions from its overseas business. However, operating profit declined 10.6% to 4.9 billion yen as higher R&D and sales promotion expenses outpaced gross profit growth, while the cost of sales ratio rose due to the consolidation of overseas operations and the SG&A ratio increased with intensified development and marketing activities, highlighting a strategic shift toward longer-term growth investment at the expense of short-term margins.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2610.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange that develops, manufactures, and sells prescription drugs, with a growing focus on both domestic and overseas markets. The company invests significantly in research and development and sales promotion to strengthen its product pipeline and expand its presence in international pharmaceutical markets.
Average Trading Volume: 89,816
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen66.48B
For a thorough assessment of 4886 stock, go to TipRanks’ Stock Analysis page.